A platform for Screening Diseases from Radiological Image using Artificial Intelligence

Ibsyn Scientific, 75C Park Street, Kolkata.

 ABOUT US

Kaustav Chakraborty Arnab Majumdar Satrajit Kanjilal Santanu Mondal

Director PhD (Physics) MS (Biotechnology) PhD (Physics)
Ibsyn Scientific Private Limited IIT Kanpur, Boston University Jawaharlal Nehru University Saha Institute of Nuclear Physics

Bipasha Bhowmik Suvadeep Panthy Sumit Rudra Ashes Ganguly

PhD (Physics) BE (Mechanical Engineering) BE (Electronics & Telecom) MS (Computer Science)
Calcutta University Nagpur University Jadavpur University IISc, University of North Carolina

ALUMNI COLLABORATORS

Rahul Singh Nachiket Gokhale Dr. Diptendra Sarkar Dr. Indranath Ghosh
BTech (Information Technology) PhD (Mechanical Engineering) Surgical Oncologist Pulmonologist
MAKA University of Technology Boston University IPGMER, Kolkata NBMC, Siliguri

Collectively, the team has about 120 years of experience in science and technology with over fifty
publications in international research journals. Over the past ten years, we have built and delivered
data-driven applications in healthcare backed by artificial intelligence. Members of the team have
consulted for a variety of global entities, such as The World Bank Group, UNICEF, USAID, The Flu
Why Us? Coalition, and KPMG. Ibsyn Scientific Private Limited has been operational since 2019 with Arnab
and Kaustav as directors. We have experience working with various government bodies such as Dr.
YSR Aarogyasri Health Care Trust, National Institute of Cholera and Enteric Diseases, National AIDS
Research Institute, Ordnance Factory Board, and West Bengal Pollution Control Board.
TUBERCULOSIS
Morbidity (infections per capita)

In 2022

Diagnosed

Mortality (deaths per capita)

10.6 Million

Death
1.28 Million
BREAST CANCER
Morbidity (infections per capita)

In 2020

Diagnosed
2.3 Million
Mortality (deaths per capita)

Death
0.68 Million
 GLOBAL TUBERCULOSIS TESTING
MARKET SIZE AND FUNDING

$ 3 Billion
2030-31

2022-23
$1.5 – 2.3 billion

Source: Mordor Intelligence and WHO database

 GLOBAL BREAST CANCER TESTING
MARKET SIZE AND FUNDING

$ 45 - 81 Billion
2030-32

2022-23
$17 – 31 billion

Global funding for cancer research between 2016 and 2020: a content analysis of public and philanthropic investments - The Lancet Oncology
 MARKET SIZE, SEGMENTATION & COMPETITION

The global AI in healthcare market size expected to grow from

Market just under $5 billion in 2020 to $45.2 billion by 2026
Size https://www.forbes.com/sites/forbestechcouncil/2021/04/28/the-current-state-of-the-
healthcare-ai-revolution/?sh=7eb97be2980d

https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-aiml-enabled-medical-devices
 THE PROBLEM

Lack of Population-Level Expensive & Unscalable Global Shortage of

Screening Methodology Radiologists
Current modes of screening Although X-Ray and USG machines
Tuberculosis, Breast Cancer, and
(Genexpert for TB and Mammography are readily available in most
similar diseases are treatable if
for Breast Cancer) are expensive countries, there is a global shortage of
detected early. Large-scale population
and/or unavailable, making these radiologists especially in rural areas
screening is thus necessary.
methods difficult to scale to and developing countries.
population level.

OUR SOLUTION

SCALABLE
ACCESSIBLE
A platform for screening diseases from Radiological images
AFFORDABLE using Artificial Intelligence
 THE PRODUCT: Radiaide

Developed by Ibsyn Scientific Private Limited (https://ibsyn-scientific.com)

Identification and
Identification of Classification of Breast
Tuberculosis from Cancer from USG and
Chest X-rays patient information
(in development)

INTELLIGENCE
Automatically identifies region of
interest, uses hierarchical
ensemble of specialized neural
network models and explains
results using Grad-CAM
PLATFORM
Provides authentication and
security, processes multiple image
formats using asynchronous APIs
with AI microservices
INTERFACE
Progressive Web Application,
usable on desktops, tablets and
mobile phones, provides AI output
with confidence, overlays and user
corrections
 TRACTION

Chest X-Ray Analysis and Tuberculosis Detection Using CNN

Relevant Proceeding of Fifth International Conference on Microelectronics, Computing and
Publications Communication Systems
https://link.springer.com/chapter/10.1007/978-981-16-0275-7_43

Screening Tuberculosis from Chest X-Rays

Clinical trial running in collaboration with North Bengal Medical College, Siliguri.

Research Screening for Tuberculosis Preventive Therapy eligible candidates with AI

Collaborations algorithms
Clinical trial running in collaboration with North Bengal Medical College, Siliguri.

Screening Breast Cancer from Ultrasonography Images

Grant submitted for model development and clinical trial in collaboration with the Institute
of Postgraduate Medical Education and Research, Kolkata.
 TRACTION

Cachexia and Tuberculosis

Proposals Biotechnology Industry Research Assistance Council (BIRAC), Grand Challenges India

Submitted Programme

In collaboration with Chittaranjan National Cancer Institute, New Town, Kolkata

Differentiation od Pulmonary TB from Lung Cancers

Tata Medical Centre, Kolkata

Staging and Margin detection in Ovarian Cancers

In discussions Institute of Postgraduate Medical Education and Research, Kolkata.

Detection of Normal Pressure Hydrocephalous and Diffuse Axonal Injury from

Brain MRI
Calcutta Medical Research Institute

etc
 MARKETS

India Developing Countries USA & Europe

Year 1+ Year 2+ Year 3+

CLIENTELE

Government Business Professionals

Health Centers, Hospitals Hospitals, Insurance, Physicians, radiologists
Diagnostic Centers

PLAN

Year 1 Year 2 Year 3

● Engage Governments & ● Scale up in India ● Scale up in India
Businesses in India ● Engage in Developing ● Scale in Developing
● Engage Research in India Countries Countries
& United States ● Clinical Study for US FDA ● US FDA Approval and

CHALLENGES
• ~67% rural population providing the
labour force with limited health
access
• Official estimate ~3M patients (=
0.3% population)
• Poor coverage of remote, tribal and
backward areas (only 6% case
finding)
• Drug resistance TB
• Latent TB
• Significantly impacting productive
age groups of 15-44 especially in
men
• Associated risk factors like tobacco,
HIV, malnourishment and living
conditions rampant
• ~1500 MD Radiologists / year
• Only ~35% utilisation of Chest X
Rays
• ~70% testing target achieved
TUBERCULOSIS ROAD MAP – INDIA
KEY CONSIDERATIONS
A. GUIDELINE
The WHO recommends large scale screening
for disease burden at ~0.5% which would
imply > 100,000 tests/hour/day – a scalability
that is impossible by current methods of TB
Diagnostics
B. GOVERNMENTAL PUSH
• National TB Eradication Plan with goal of
zero new cases by 2035
• 3,400 Cr Budget (2022)
• ~25k primary care centres >65% of which
have chest X ray facilities
• ~93% of which are covered by cellular
networks of 3G or above
• Public Private partnerships in major
areas of diagnostics using the ~1.5
Million Chest X ray machines in India
OUR STRENGTHS
We believe the Radiaide TB would assist in
screening patients / populations in situ, with or
without PPP model or handheld X ray devices or
mobile photographs of chest x rays. It would
provide an accurate, scalable and cost-effective
model that needs no other infrastructure or
manpower while reducing costs ~ 6X than that of
the current point of care PCR tests like the
Genexpert or True NATs. Further the same model
can be easily retrained for future disease
diagnostics and added on to the existing.
OUR PLAN OVERVIEW
• Approach MoHFW, Govt of India, with data for
inclusion into NTEP to boost coverage, access
etc
• Approach individual states with low utilisation
of chest X rays
• Over next 7 years, Radiaide TB should be a
part of the 24 AIIMS level, 300 medical
colleges, 736 district hospitals, apart from the
PHCs mentioned.
• Approach major private players with network
units wherein Radiaide TB can be integrated
into telemedicine.

CHALLENGES
• Target age group of 35- 65 year old
women 170 Million
• ~69% of above in non-urban
locations
• ~26% of all cancers in women
• ~150,000 new cases per year with
incidence of ~25 per 100,000
population (Global 18 per 100,000
population)
• 5 year survival rate ~65% (global ~
82%)
• In the age group mentioned above,
cases increasing !11% p.a
• ~78% of the cases undergo
mastectomy(ies) where the gloab
average ~20% showing probable
impact of late diagnosis
• Social norms
• No screening program in place yet
• No mechanism to predict success of
surgery or radiation / anti-cancer
drugs / horomone therapy or
relapse thereafter
• Minimal access in private
healthcare generally cost
prohibitive
BREAST CANCER ROAD MAP – INDIA
KEY CONSIDERATIONS
A. GUIDELINE
Global Breast Cancer Initiative (2021)
strategy overview -
1. Health promotion for early detection to
achieve atleast 60% cases in stage I or II
2. Timely and definitive diagnosis within 60
days
3. Multimodal treatment that is carried till
completion of regimen for atleast 80%
of positive cases
B. LESSONS
• Kenya study: Implementing early
diagnosis through Clinical Breast
Examination + Mammography would
likely improve stage I and II from 31%
(2020) to 69% (2040)
• Mumbai study: Just a CBE mediated
screening could reduce mortality by 50%
over 20 years
• etc
OUR STRENGTHS
We believe the Radiaide Breast Cancer model, like
the TB model, healthcare access in situ to the
69% non-urban women where cases are seen to
be growing ~11% p.a thereby providing India with
a modality of compliance to pillar 1, ie Early
Detection in the GBCI
OUR PLAN OVERVIEW
• ~2700 Ultrasound machines in West Bengal;
~22 million women in the age group 35-65 y.o.
incl 1350 PNCs equipped with 1100 US
machines.
• Scale up through MoHFW, Govt of India to
88,000 US units using data from above
• Develop Call / Recall module integrated with
currently available databases of age, sex and
contact for increased access in early detection
• Develop Image processing for biopsies to
increase compliance to pillar 2 of the GBCI – ie
definitive diagnosis
• Develop module for integration of gene
expression studies of genetic markers of
breast cancer to predict the outcome of
therapy initiated
TENTATIVE RADIAIDE DEVELOPMENT PLAN

Time in years

+2 +3
NOW +1
Functionalities
1. Tuberculosis 1. Pneumonia 1. Lung cancer 1. Cachexia and
from chest X rays from CT / MRI TB
2. COVID-19
2. Pneumonia 2. Predictive 2. Normal
(partly trained) 3. Breast Cancer algorithm for Pressure
from ultrasound success of breast Hydrocephalous
cancer therapy
using genetic
4. Latent markers 3. Diffuse Axonal
Tuberculosis case Injury
finding algorithm
3. Ovarian cancer
5. active / “old” TB staging and
differentiation from margin detection
chest x rays

$150K - $200K
● Product polish
● Team Base Salaries (1Y)
● Sales & Travel Costs
● Cloud Costs
ASK
$500K - $1M $5M
● Multinational expansion
● Product expansion
● US FDA Approval
● Team Salaries (1Y)
● Marketing, Sales &
Support
● Clinical Studies
Conclusion
The importance of radiological imaging in diagnostic workflows in well established. Addition of
modern tools like Artificial Intelligence will play key role in increasing access to healthcare and early
detection for better prognostic outcomes and therefore reduce associated costs therein. The last
decade has seen a boom in research applications of AI in numerous clinical scenarios; the FDA
approvals bear a testimony to the focus thereupon. There are newer recommendations from apex
institutions like the WHO which encourage adoption of such technologies and lay down guidelines
that provide a framework for assessment of the performance of these tools.

Through the preceding slides, we have attempted to showcase our product – the Radiaide - as is
today, the future add-ons as we see them, their roles in tackling two of the high burden / mortality
scenarios prevalent in the world and our country. Our belief is driven by various factors, such as
need, complexity of the issue, gaps, recommendations from agencies, funding and opportunities to
monetise through enablement of quality services.